

Katherine McNamara

- MD Student, expected graduation Spring 2022
- Ph.D. Student in Cancer Biology, admitted Summer 2016
- MSTP Student

Publications

PUBLICATIONS

- **Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response** *NATURE CANCER*
McNamara, K. L., Caswell-Jin, J. L., Joshi, R., Ma, Z., Kotler, E., Bean, G. R., Kriner, M., Zhou, Z., Hoang, M., Beechem, J., Zoeller, J., Press, M. F., Slamon, et al
2021; 2 (4): 400-+
- **Characterizing the tumor and immune microenvironment through treatment to predict response to neoadjuvant HER2-targeted therapy using the Digital Spatial Profiler**
McNamara, K., Caswell-Jin, J. L., Ma, Z., Zoeller, J. J., Kriner, M., Zhou, Z., Reeves, J., Hoang, M., Beechem, J., Slamon, D. J., Press, M. F., Brugge, J., Hurvitz, et al
AMER ASSOC CANCER RESEARCH.2020
- **Tumor expression and microenvironment in HER2-positive breast cancer before and on HER2-targeted therapy: Analysis of microarray expression data from the TRIO-US B07 trial**
Caswell-Jin, J. L., McNamara, K. L., Dering, J., Chen, H., Dichmann, R., Perez, A., Patel, R., Kotler, E., Zoeller, J. J., Brugge, J. S., Press, M. F., Slamon, D. J., Curtis, et al
AMER ASSOC CANCER RESEARCH.2020
- **Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07).** *Nature communications*
Hurvitz, S. A., Caswell-Jin, J. L., McNamara, K. L., Zoeller, J. J., Bean, G. R., Dichmann, R., Perez, A., Patel, R., Zehngbot, L., Allen, H., Bosserman, L., DiCarlo, B., Kennedy, et al
2020; 11 (1): 5824
- **Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing.** *eLife*
Baslan, T. n., Kendall, J. n., Volyansky, K. n., McNamara, K. n., Cox, H. n., D'Italia, S. n., Ambrosio, F. n., Riggs, M. n., Rodgers, L. n., Leotta, A. n., Song, J. n., Mao, Y. n., Wu, et al
2020; 9
- **Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy** *NATURE COMMUNICATIONS*
Caswell-Jin, J. L., McNamara, K., Reiter, J. G., Sun, R., Hu, Z., Ma, Z., Ding, J., Suarez, C. J., Tilk, S., Raghavendra, A., Forte, V., Chin, S., Bardwell, et al
2019; 10
- **Clonal replacement of tumor-specific T cells following PD-1 blockade.** *Nature medicine*
Yost, K. E., Satpathy, A. T., Wells, D. K., Qi, Y. n., Wang, C. n., Kageyama, R. n., McNamara, K. L., Granja, J. M., Sarin, K. Y., Brown, R. A., Gupta, R. K., Curtis, C. n., Bucktrout, et al
2019
- **Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.** *Nature communications*
Caswell-Jin, J. L., McNamara, K. n., Reiter, J. G., Sun, R. n., Hu, Z. n., Ma, Z. n., Ding, J. n., Suarez, C. J., Tilk, S. n., Raghavendra, A. n., Forte, V. n., Chin, S. F., Bardwell, et al
2019; 10 (1): 657
- **Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy.** *Nature communications*
Caswell-Jin, J. L., McNamara, K. n., Reiter, J. G., Sun, R. n., Hu, Z. n., Ma, Z. n., Ding, J. n., Suarez, C. J., Tilk, S. n., Raghavendra, A. n., Forte, V. n., Chin, S. F., Bardwell, et al

2019; 10 (1): 2433

- **Harnessing Tumor Evolution to Circumvent Resistance.** *Trends in genetics : TIG*
Pogrebniak, K. L., Curtis, C.
2018